Disrupting the SATB2/CBP complex significantly inhibited tumor growth by inhibiting FOXM1 expression, indicating that targeting the SATB2/CBP signaling axis may have therapeutic potential to improve GBM treatment. The gene discussed is SATB2; the disease is glioblastoma.